49,680 Shares in Intellia Therapeutics, Inc. $NTLA Purchased by Grandfield & Dodd LLC

Grandfield & Dodd LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 49,680 shares of the company’s stock, valued at approximately $841,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Oppenheimer & Co. Inc. increased its holdings in shares of Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after purchasing an additional 808 shares during the period. Comerica Bank lifted its position in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after purchasing an additional 901 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Intellia Therapeutics by 36.4% during the first quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after purchasing an additional 948 shares during the period. Wealthfront Advisers LLC boosted its holdings in shares of Intellia Therapeutics by 7.6% during the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock worth $185,000 after purchasing an additional 1,018 shares during the period. Finally, Benjamin Edwards Inc. grew its position in Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after purchasing an additional 1,126 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NTLA shares. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Morgan Stanley lifted their target price on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a research note on Monday, April 27th. Sanford C. Bernstein boosted their price target on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $49.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, June 16th. Finally, Wall Street Zen lowered Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $21.15.

Intellia Therapeutics Stock Up 1.5%

NTLA stock opened at $12.09 on Tuesday. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -3.60 and a beta of 1.81. Intellia Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $28.25. The firm has a 50 day moving average of $13.45 and a two-hundred day moving average of $13.38.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. During the same period last year, the company earned ($0.98) earnings per share. The business’s revenue was down 46.4% compared to the same quarter last year. On average, research analysts expect that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. This trade represents a 2.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the transaction, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.50% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.